RAGE: A novel biological and genetic marker for vascular disease

Anastasia Z. Kalea, Ann Marie Schmidt, Barry Hudson

Research output: Contribution to journalArticle

125 Citations (Scopus)

Abstract

RAGE [receptor for AGEs (advanced glycation end-products)] plays an important role in the development and progression of vascular disease. Studies in cultured cells and small animal models of disease have clearly demonstrated that RAGE is central to the pathogenesis of vascular disease of the macro- and micro-vessels in both the diabetic and non-diabetic state. Emerging results from human clinical studies have revealed that levels of circulating soluble RAGE in the plasma may reflect the presence and/or extent of vascular disease state. Additionally, genetic variants of the RAGE gene (AGER in HUGO nomenclature) have been associated with vascular disease risk. Combining RAGE circulating protein levels and the presence of particular RAGE polymorphisms may be a useful clinical tool for the prediction of individuals at risk for vascular disease. Therapeutic intervention targeted at the RAGE gene may therefore be a useful means of treating pathologies of the vasculature.

Original languageEnglish
Pages (from-to)621-637
Number of pages17
JournalClinical Science
Volume116
Issue number8
DOIs
StatePublished - Apr 1 2009
Externally publishedYes

Fingerprint

Genetic Markers
Vascular Diseases
Biomarkers
Animal Disease Models
Terminology
Genes
Cultured Cells
Pathology
Proteins
Therapeutics

Keywords

  • Advanced glycation end-product (AGE)
  • Diabetes
  • Gene polymorphism
  • Receptor for advanced glycation end-products (RAGE)
  • Vascular disease

ASJC Scopus subject areas

  • Medicine(all)

Cite this

RAGE : A novel biological and genetic marker for vascular disease. / Kalea, Anastasia Z.; Schmidt, Ann Marie; Hudson, Barry.

In: Clinical Science, Vol. 116, No. 8, 01.04.2009, p. 621-637.

Research output: Contribution to journalArticle

Kalea, Anastasia Z. ; Schmidt, Ann Marie ; Hudson, Barry. / RAGE : A novel biological and genetic marker for vascular disease. In: Clinical Science. 2009 ; Vol. 116, No. 8. pp. 621-637.
@article{3a46dca5a689489a94f3dc4504c494dd,
title = "RAGE: A novel biological and genetic marker for vascular disease",
abstract = "RAGE [receptor for AGEs (advanced glycation end-products)] plays an important role in the development and progression of vascular disease. Studies in cultured cells and small animal models of disease have clearly demonstrated that RAGE is central to the pathogenesis of vascular disease of the macro- and micro-vessels in both the diabetic and non-diabetic state. Emerging results from human clinical studies have revealed that levels of circulating soluble RAGE in the plasma may reflect the presence and/or extent of vascular disease state. Additionally, genetic variants of the RAGE gene (AGER in HUGO nomenclature) have been associated with vascular disease risk. Combining RAGE circulating protein levels and the presence of particular RAGE polymorphisms may be a useful clinical tool for the prediction of individuals at risk for vascular disease. Therapeutic intervention targeted at the RAGE gene may therefore be a useful means of treating pathologies of the vasculature.",
keywords = "Advanced glycation end-product (AGE), Diabetes, Gene polymorphism, Receptor for advanced glycation end-products (RAGE), Vascular disease",
author = "Kalea, {Anastasia Z.} and Schmidt, {Ann Marie} and Barry Hudson",
year = "2009",
month = "4",
day = "1",
doi = "10.1042/CS20080494",
language = "English",
volume = "116",
pages = "621--637",
journal = "Clinical Science",
issn = "0143-5221",
publisher = "Portland Press Ltd.",
number = "8",

}

TY - JOUR

T1 - RAGE

T2 - A novel biological and genetic marker for vascular disease

AU - Kalea, Anastasia Z.

AU - Schmidt, Ann Marie

AU - Hudson, Barry

PY - 2009/4/1

Y1 - 2009/4/1

N2 - RAGE [receptor for AGEs (advanced glycation end-products)] plays an important role in the development and progression of vascular disease. Studies in cultured cells and small animal models of disease have clearly demonstrated that RAGE is central to the pathogenesis of vascular disease of the macro- and micro-vessels in both the diabetic and non-diabetic state. Emerging results from human clinical studies have revealed that levels of circulating soluble RAGE in the plasma may reflect the presence and/or extent of vascular disease state. Additionally, genetic variants of the RAGE gene (AGER in HUGO nomenclature) have been associated with vascular disease risk. Combining RAGE circulating protein levels and the presence of particular RAGE polymorphisms may be a useful clinical tool for the prediction of individuals at risk for vascular disease. Therapeutic intervention targeted at the RAGE gene may therefore be a useful means of treating pathologies of the vasculature.

AB - RAGE [receptor for AGEs (advanced glycation end-products)] plays an important role in the development and progression of vascular disease. Studies in cultured cells and small animal models of disease have clearly demonstrated that RAGE is central to the pathogenesis of vascular disease of the macro- and micro-vessels in both the diabetic and non-diabetic state. Emerging results from human clinical studies have revealed that levels of circulating soluble RAGE in the plasma may reflect the presence and/or extent of vascular disease state. Additionally, genetic variants of the RAGE gene (AGER in HUGO nomenclature) have been associated with vascular disease risk. Combining RAGE circulating protein levels and the presence of particular RAGE polymorphisms may be a useful clinical tool for the prediction of individuals at risk for vascular disease. Therapeutic intervention targeted at the RAGE gene may therefore be a useful means of treating pathologies of the vasculature.

KW - Advanced glycation end-product (AGE)

KW - Diabetes

KW - Gene polymorphism

KW - Receptor for advanced glycation end-products (RAGE)

KW - Vascular disease

UR - http://www.scopus.com/inward/record.url?scp=66949157648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66949157648&partnerID=8YFLogxK

U2 - 10.1042/CS20080494

DO - 10.1042/CS20080494

M3 - Article

C2 - 19275767

AN - SCOPUS:66949157648

VL - 116

SP - 621

EP - 637

JO - Clinical Science

JF - Clinical Science

SN - 0143-5221

IS - 8

ER -